These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18636037)

  • 1. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.
    Clark JJ; Provenzano M; Diggelmann HR; Xu N; Hansen SS; Hansen MR
    Otol Neurotol; 2008 Sep; 29(6):846-53. PubMed ID: 18636037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of vestibular schwannoma cells with ErbB inhibitors.
    Bush ML; Burns SS; Oblinger J; Davletova S; Chang LS; Welling DB; Jacob A
    Otol Neurotol; 2012 Feb; 33(2):244-57. PubMed ID: 22222570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801.
    Dougherty MC; Shibata SB; Clark JJ; Canady FJ; Yates CW; Hansen MR
    J Neurosurg; 2023 Apr; 138(4):962-971. PubMed ID: 36087315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
    Bachawal SV; Wali VB; Sylvester PW
    BMC Cancer; 2010 Mar; 10():84. PubMed ID: 20211018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.
    Ritter CA; Bianco R; Dugger T; Forbes J; Qu S; Rinehart C; King W; Arteaga CL
    Int J Clin Pharmacol Ther; 2004 Nov; 42(11):642-3. PubMed ID: 15598031
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
    Lu YY; Jing DD; Xu M; Wu K; Wang XP
    World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
    Sánchez-Martín M; Pandiella A
    Int J Cancer; 2012 Jul; 131(1):244-52. PubMed ID: 21826647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
    McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
    J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
    Ritter CA; Perez-Torres M; Rinehart C; Guix M; Dugger T; Engelman JA; Arteaga CL
    Clin Cancer Res; 2007 Aug; 13(16):4909-19. PubMed ID: 17699871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
    Holtkamp N; Malzer E; Zietsch J; Okuducu AF; Mucha J; Mawrin C; Mautner VF; Schildhaus HU; von Deimling A
    Neuro Oncol; 2008 Dec; 10(6):946-57. PubMed ID: 18650488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
    Atkinson DM; Clarke MJ; Mladek AC; Carlson BL; Trump DP; Jacobson MS; Kemp BJ; Lowe VJ; Sarkaria JN
    Head Neck; 2008 Jun; 30(6):790-9. PubMed ID: 18286491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
    Friess T; Scheuer W; Hasmann M
    Clin Cancer Res; 2005 Jul; 11(14):5300-9. PubMed ID: 16033849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.
    Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF
    Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
    Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
    J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.